Impact of GLP-1 Medications on Muscle Health in Postmenopausal Women
When initiating GLP-1 medication after menopause, it is common to focus primarily on weight loss. However, weight loss can have implications beyond just changes in body weight; it can also lead to a reduction in lean tissue, including muscle. Given that menopause already presents challenges in maintaining muscle mass, understanding the interplay between weight loss and muscle health during this period is crucial.
A recent narrative review investigated the effects of semaglutide, a GLP-1 medication, on muscle health in postmenopausal women, particularly concerning strength and physical function during weight loss. The researchers reviewed existing studies that focused on semaglutide, postmenopausal women, body composition, muscle health, and sleep-disordered breathing. Their goal was to synthesize the available evidence regarding how to preserve muscle while utilizing semaglutide for weight management.
The timing of treatment is significant, as lower estrogen levels after menopause are associated with changes in body composition, including increased abdominal fat and gradual muscle loss. Therefore, maintaining strength becomes an essential aspect of healthy aging. One study included in the review tracked adults with obesity, predominantly women, throughout their semaglutide treatment. Researchers measured body composition and grip strength at the beginning of the study, as well as at seven and twelve months into treatment.
The findings revealed that lean mass initially decreased but then stabilized. In contrast, grip strength showed significant improvement at both follow-up points. Additionally, the incidence of sarcopenic obesity—characterized by low muscle mass coupled with high body fat—decreased during the study period. It is important to note that lean mass and muscle strength are not synonymous; a scan may indicate a reduction in lean mass without necessarily implying a loss of strength.
The evidence presented in the review does have limitations. Notably, the study was not exclusively conducted on postmenopausal women and lacked a comparison group, which means the results cannot be generalized to all women taking semaglutide after menopause. Furthermore, relying solely on the scale to gauge progress can be misleading; it does not account for potential declines in muscle strength.
Everyday functional abilities, such as grip strength, walking speed, and the ability to rise from a seated position, are highlighted as valuable indicators of physical function. These measures can provide a more comprehensive understanding of muscle health than body composition metrics alone, which is particularly relevant after menopause when preserving muscle is vital for maintaining mobility and independence as one ages.
The review suggests two practical approaches to support muscle and physical function during weight loss: focusing on strength and physical function alongside adequate protein intake and engaging in resistance training can help mitigate muscle loss as the body undergoes changes during and after menopause. Overall, the findings underscore that the number on the scale represents only a fraction of the overall picture when it comes to weight loss after menopause.




